Sign In
Buy ARWR
$82.00
+0.180 (+0.220%)
At Close: Jun 22, 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved REDEMPLO (plozasiran), a small
Arrowhead Pharmaceuticals: Important Catalysts And Some Challenges Ahead
10:08am, Monday, 17'th Nov 2025
A busy period is ahead for Arrowhead Pharmaceuticals on regulatory, legal, and clinical fronts. The PDUFA date with the FDA for plozasiran is tomorrow, and an approval should be expected, but competit
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
04:30pm, Thursday, 06'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 25, 2025, at 4:30 p.m. ET to dis
World Investment Advisors Sells 4,780 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
04:00am, Thursday, 06'th Nov 2025
World Investment Advisors cut its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 25.8% during the undefined quarter, according to the company in its most recent 13F filing with t
Privium Fund Management Sells Into Strength in Pharma Stock
10:42am, Tuesday, 04'th Nov 2025
Sold 138,263 shares of Arrowhead Pharmaceuticals; Estimated transaction value: $3,039,518 Post-trade stake: 473,951 shares valued at $16.35 million as of September 30, 2025 Arrowhead Pharmaceuticals n
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
07:30am, Tuesday, 04'th Nov 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: American Heart Associa
Mutual of America Capital Management LLC Has $255,000 Stake in Arrowhead Pharmaceuticals, Inc. $ARWR
04:32am, Thursday, 30'th Oct 2025
Mutual of America Capital Management LLC trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 12.1% in the second quarter, according to the company in its most recent Form 13F fil
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Tuesday, 28'th Oct 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
07:30am, Tuesday, 21'st Oct 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on S
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals
07:30am, Thursday, 11'th Sep 2025
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that yesterday it filed a Complaint for Declaratory Judgment in the United States District C
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
02:55pm, Wednesday, 10'th Sep 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & P
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
01:42pm, Tuesday, 09'th Sep 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & P
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Cantor Global Healthcare Conference 2025 Transcript
09:35pm, Sunday, 07'th Sep 2025
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Cantor Global Healthcare Conference 2025 September 4, 2025 9:10 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President Conferen
